Engflag

Succimer

Quick links to important sections

Succimer

Succimer_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Succimer

Property Description
Active Ingredient meso-2,3-dimercaptosuccinic acid (DMSA)
Form Oral capsule
Pharmacological Class Heavy metal chelating agent
Common Use Reducing toxic metal levels in the body
Origin Synthetic (chemically synthesized)

What Type of Medicine is Succimer?

Succimer is a synthetic, prescription-only medication primarily identified as a specialized heavy metal chelating agent. It is classified as an antidote and is one of the essential tools used to address the effects of toxic metal accumulation within the body. Its core identity is defined by its single active ingredient: meso-2,3-dimercaptosuccinic acid, commonly abbreviated as DMSA.

DMSA is characterized as an orally active drug within this class. This means the medicine can be taken by mouth, distinguishing it from related treatments that may require injections. One notable formulation is marketed under the brand name Chemet, typically available as a 100 mg oral capsule.

Composition and The Principle of Chelation

The active substance, Succimer (DMSA), is a dithiol compound that functions by engaging in a chemical process known as chelation to manage toxic metal levels. This mechanism involves the drug acting like a molecular trap, where its unique structure allows it to bind tightly to certain circulating heavy metal ions, such as lead.

The binding action effectively sequesters the metal, preventing it from interacting with the body's tissues and forming a stable, water-soluble complex. The drug is specifically classified as a metal-chelating agent for lead. This confirms the medicine is designed to work by binding and removing metals from the body. Succimer is a single-ingredient product, containing only DMSA alongside standard solid excipients within the capsule shell.

General Purpose: An Orally Active Antidote

Succimer's general purpose is to lower the overall toxic burden of heavy metals, functioning as an orally active antidote for metal exposure. Its action is geared toward accelerating the natural detoxification pathway. A typical use scenario involves administering Succimer when laboratory tests confirm high levels of lead in the body. By converting the toxic metal into a water-soluble form through chelation, Succimer ensures that the resulting complex can be readily filtered out of the bloodstream by the kidneys, facilitating the efficient and controlled urinary excretion of the accumulated metal.

Regulatory References

  1. NIH MedlinePlus on Succimer (DMSA)

What side effects are possible with Succimer?

Possible side effects and safety information

Succimer's safety profile, documented in official prescribing information, outlines specific patterns of adverse reactions and essential patient considerations. The drug is contraindicated in patients with a history of hypersensitivity reaction to succimer or any component of the formulation.

Classification of Adverse Reactions

The most commonly reported adverse reactions are associated with the Gastrointestinal System. Effects classified as having an incidence of 10% or greater include nausea, vomiting, diarrhea, and appetite loss. Other common digestive effects include a metallic taste in the mouth. Reactions affecting the skin are also documented, with the occurrence of a rash noted in approximately 4% of treated patients.

Clinically Significant Safety Patterns

Several adverse reactions require specific safety monitoring:

  • Hematological Concerns: Succimer has been associated with neutropenia, a reduction in a type of white blood cell, which may require temporary interruption of treatment.
  • Hepatic Concerns: Transient elevations of serum transaminases (ALT and AST) have been observed in 6% to 10% of patients. Monitoring liver function is recommended.
  • Hypersensitivity Reactions: The potential for serious hypersensitivity reactions exists, including urticaria (hives), angioedema (swelling), and mucocutaneous vesicular eruptions (blisters).

Contextual and Population Safety Notes

Official labeling highlights safety considerations for special populations and contextual patterns. The use of succimer requires the assessment of hepatic and renal function. Based on animal studies, the drug may cause fetal harm during pregnancy, necessitating caution. After the therapy is stopped, the body's natural redistribution of lead can lead to a rapid return or "rebound" of elevated blood lead levels.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Succimer

This section outlines the officially documented overdose information based on government regulatory sources.

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations: Non-clinical toxicology studies cited in the regulatory label describe ataxia, convulsions, and labored respiration following high-dose exposure. No case of human overdosage has been reported in the official prescribing information.
Physiological systems affected: Neurological and Respiratory systems, as indicated by convulsions and labored respiration.
Dose-related or exposure-related factors: Manifestations were observed in animals at high non-clinical doses (2300 mg/kg in the rat and 2400 mg/kg in the mouse).
Emergency-response statements: In case of acute overdosage, medical personnel are instructed to consider the use of induction of vomiting or gastric lavage followed by an activated charcoal slurry and appropriate supportive therapy.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification: Overdosage is associated with potentially severe and life-threatening outcomes (e.g., death), as documented in non-clinical toxicology reports.
Monitoring: Limited data are noted which indicate that the product is dialyzable.

Resulting Overdose Structure

Official overdose statements:

  • The most severe outcome documented in non-clinical toxicology is death.
  • Management of an acute overdosage event requires consideration of gastrointestinal decontamination procedures, such as induction of vomiting or gastric lavage.
  • Following decontamination, administration of appropriate supportive therapy is advised.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the Succimer overdose profile primarily through procedural mandates for decontamination and supportive care in the event of an acute overexposure. This is based on non-clinical toxicology findings which document severe manifestations, given that no cases of human overdosage have been formally reported. Urgent medical action is required for any known acute overdosage due to the high toxicity potential documented in official sources.

Therapeutic Uses of Succimer

What Succimer Treats: Main Uses and Benefits

Succimer is commonly used to help with the management of heavy metal intoxication, primarily confirmed cases of lead poisoning (plumbism). Treatment is generally indicated when blood lead concentrations reach 45 micrograms per deciliter (µg/dL) or higher.

The medication is relevant in contexts involving heightened systemic burden caused by lead accumulation, often used for both acute exposure and chronic accumulation. It contributes to easing the overall symptom load and is linked to the process of metal reduction. This process may assist with mitigating the systemic burden on organs and tissues.

Symptom Management and Patient Comfort

Succimer is considered relevant for easing symptom clusters that may become intense or disruptive and are linked to systemic metal poisoning. These include symptoms related to physical discomfort, such as persistent headache and severe constipation, alongside symptoms that create noticeable physiological strain, like profound lethargy (tiredness).

The therapy contributes to symptomatic relief during periods of heightened symptoms and helps improve day-to-day comfort during symptomatic periods. This is summarized by the simple therapeutic goal:

“The treatment is used to manage the symptoms and toxic burden associated with heavy metals.”

Therapeutic Use and Indications

Succimer is used across conditions presenting with acute episodes and chronic accumulation that produce significant symptomatic burden. Key indications include the management of elevated lead levels in pediatric patients (children aged 1 year and older). For this susceptible group, the treatment may be part of managing the overall symptomatic burden associated with metal accumulation and assisting with maintaining functional stability.

Quick Fact: Relief for Non-Specific Systemic Symptoms Succimer is commonly used to help manage the non-specific symptoms of lead exposure—including headache, lethargy, and constipation—by managing the overall toxic burden.

Eligibility and Restrictions for Use

Official Eligibility Rules for Succimer Use

Succimer is governed by strict population eligibility rules defined in regulatory labeling. Use is primarily established for pediatric patients aged 1 year and older who have confirmed blood lead levels above 45 micrograms per deciliter (μg/dL). Safety and effectiveness have not been established in children younger than one year of age.

Populations Who Must Not Use Succimer

Absolute contraindications prohibit the use of Succimer in patients with a known history of hypersensitivity reaction to the medicine or any of its components. Specific metabolic disorders, such as rare hereditary galactose intolerance, also represent a non-eligibility factor due to the capsule's excipients.

Conditional and Restricted Use

Use is restricted and requires close medical monitoring for patients with hepatic (liver) or renal (kidney) impairment.

For females of reproductive potential, effective contraception is required during treatment and for 14 days following the final dose, as the medicine may cause fetal harm. Additionally, the label states that use is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Succimer (DMSA) as described in government regulatory documents, focusing on pharmacodynamic conflicts and substance co-administration restrictions. The official interaction profile is defined primarily by the medicine’s core function as a heavy metal chelating agent, which influences how it interacts with other metal-containing substances.

Official Interaction Statements

Interaction Domain Practical Interaction Implication (Based on Regulatory Documents)
Pharmacodynamic Interaction Co-administration of Succimer with other heavy metal chelating agents, such as Edetate Calcium Disodium (CaEDTA), is officially restricted. Simultaneous use is not recommended due to the potential for conflicting effects.
Interference with Diagnostic Agents The effectiveness of the diagnostic agent Technetium Tc-99m oxidronate may be decreased by Succimer due to interference with the metal component of the agent.
Influence on Essential Element Exposure Iron supplementation must be interrupted or delayed during the full course of Succimer treatment to prevent chelation of the iron and potential adverse outcomes.

Regulatory Summary

The regulatory documents confirm that Succimer may be administered with or without food, indicating that a timing restriction separating the medicine from meals is not required. No specific pharmacokinetic interactions related to major enzyme or transporter systems are documented in the official prescribing information.

Mechanism of Action

The primary mechanism of Succimer (DMSA) involves its molecular action as a dithiol compound, meaning it contains two adjacent sulfhydryl groups ( -SH). This unique chemical structure allows the drug to selectively bind to highly reactive toxic heavy metal cations (such as lead and mercury) through a process called chelation. The outcome is the formation of a stable, chemically inert, and highly water-soluble metal-DMSA complex, thereby reducing the availability of the metal to interact with endogenous sulfhydryl groups. Once the stable, water-soluble complex is formed, the mechanism shifts to accelerated systemic elimination. The complex mobilizes the metal from soft tissues (like the liver and kidney) into the bloodstream, where it is efficiently filtered by the renal glomeruli. This action accelerates the metal's slow natural clearance kinetics, leading to an increase in the metal's urinary excretion and a corresponding, controlled reduction in the total accumulated metal content within the body. The drug's mechanism is constrained by physiological compartmentalization, limiting its effectiveness in specific areas. Succimer has poor access to and limited ability to mobilize metal that is tightly sequestered in long-term storage sites, notably skeletal lead stores in bone tissue. This limitation reflects the potential for metal redistribution into the circulation from storage compartments when soft tissue concentrations decrease.

Dosage and Administration Information

How to Use Succimer: Administration Guidelines

Succimer (DMSA) is a prescription medication administered according to a specific, two-phase regimen. Its use is restricted to certain pediatric patients and requires adherence to scheduling and duration guidelines.

Administration Scope

Feature Instruction
Route of Administration Oral administration only, using the 100 mg capsule form.
Dosing Schedule Initial Phase (5 Days): 10 mg/kg or 350 mg/m^2 per dose. Maintenance Phase (14 Days): The same dose is continued.
Frequency and Duration Initial: Administered every 8 hours (q8h) for 5 days. Maintenance: Administered every 12 hours (q12h) for 14 days. The total course is 19 days.
Preparation Requirements Capsules should be administered whole when possible. For patients who cannot swallow the capsule, the contents may be sprinkled on a small amount of soft food or given on a spoon followed by a fruit drink.
Age-Group Rules The medication is indicated for patients aged 1 year and older. Its safety and effectiveness are not established in children less than 1 year of age.
Special Procedural Conditions Patients must be maintained with adequate fluid intake throughout the course of therapy. The source of environmental lead exposure must be identified and eliminated before treatment begins.

Resulting Use Protocol

The administration protocol follows a structured regimen for using succimer. The process establishes a fixed 19-day cycle that shifts in frequency from three times daily to twice daily after the initial 5 days. This treatment course must be separated from any subsequent course by a minimum of two weeks (14 days) off the medication. Application is based on specific parameters regarding the patient's age and requires attention to environmental control and hydration status.

Recent Clinical Evidence

Succimer (meso-2,3-dimercaptosuccinic acid, or DMSA) is an orally administered chelating agent primarily studied for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 micrograms per deciliter (mu g/ dL). As a chelator, it is thought to bind with lead ions, forming a water-soluble complex that is subsequently removed from the body through the kidneys, thereby enhancing urinary lead excretion.

Findings on Efficacy and Outcome

Clinical trials consistently show that succimer administration results in an abrupt reduction in blood lead concentrations, followed by a rebound rise after treatment is stopped, as lead redistributes from storage sites (such as bone) into the blood.

  • Pediatric Trials: A large, randomized, placebo-controlled trial in children with moderate blood lead levels (25-44mu g/ dL) found that while succimer lowered blood lead levels, it did not provide evidence of benefit in long-term clinical or neurocognitive outcomes. For patients with higher levels, succimer has been found to be comparable to intravenous calcium EDTA in reducing blood lead concentrations.

Safety and Expanded Use

Succimer is generally considered well tolerated for its approved indication. However, it is not approved for the prevention of lead poisoning or for use in lead-contaminated environments. Studies have also investigated its potential use in cases of inorganic mercury and arsenic poisoning, where it has shown an ability to increase the urinary excretion of these metals, though evidence for definitive therapeutic efficacy in these off-label contexts remains limited. Monitoring of liver function and complete blood counts is routinely recommended during treatment.

Frequently Asked Questions (FAQ)

Common questions about Succimer (FAQ)

Q: What is the official brand name for the Succimer drug?

The active ingredient succimer is marketed under the official brand name CHEMET in the United States. This designation is provided in the FDA-approved product labeling for the oral capsule formulation.

Q: If I miss a dose of Succimer, what should I do (take it late, skip it, etc.)?

Official regulatory documents contain general guidance stating that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the instruction is to skip the missed dose entirely and resume the regular dosing schedule. The label specifies that a double dose should not be taken to make up for a missed dose.

Q: When should I take my child back to the doctor after the treatment to check the lead level?

After a course of therapy is finished, monitoring is recommended for the potential rebound of blood lead levels, which can occur as lead redistributes in the body. Official labeling states that blood lead levels are typically measured at least once weekly until they stabilize at an acceptable concentration, ensuring treatment success.

Q: Can adults with high lead levels also take Succimer?

The FDA-approved indication for succimer is specifically for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 micrograms per deciliter. Official prescribing information states the drug's safety and effectiveness have not been established for other age groups or conditions, including adults with high lead levels.

How should Succimer be stored and disposed of?

Storage and Disposal of Succimer Capsules

Succimer capsules must be stored according to official regulatory requirements to ensure product stability. The medicine must be kept at controlled room temperature, specifically between 15°C and 25°C (59°F and 77°F), and protected from light and excessive heat .

Handling and Safety

The container must remain tightly closed and storage must prevent freezing or exposure to moisture. Succimer must be stored strictly out of the reach of children.

Disposal Instructions

Unused or expired capsules should be discarded through an official drug take-back program. If a take-back option is unavailable, the product must be mixed with an unappealing substance, placed in a sealed bag, and disposed of in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Succimer found in:

A-Z Index: